News Gilead swoops to buy Kite for $12billion Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
